ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,604,250 | -80.7% | 45,000 | -75.0% | 0.02% | -83.8% |
| Q2 2023 | $8,303,400 | +165.4% | 180,000 | +130.7% | 0.15% | +146.7% |
| Q1 2023 | $3,128,762 | +48.4% | 78,024 | +71.5% | 0.06% | +87.5% |
| Q4 2022 | $2,108,015 | -80.2% | 45,500 | -82.3% | 0.03% | -78.2% |
| Q3 2022 | $10,643,000 | -45.2% | 257,100 | -21.0% | 0.15% | -45.1% |
| Q2 2022 | $19,422,000 | +192.7% | 325,534 | +256.2% | 0.27% | +235.0% |
| Q1 2022 | $6,636,000 | -27.3% | 91,400 | +14.0% | 0.08% | -59.2% |
| Q1 2021 | $9,131,000 | +140.7% | 80,201 | +192.7% | 0.20% | +127.9% |
| Q4 2020 | $3,794,000 | -14.5% | 27,400 | -49.3% | 0.09% | -17.3% |
| Q3 2020 | $4,436,000 | -48.3% | 54,000 | -50.8% | 0.10% | -63.6% |
| Q2 2020 | $8,581,000 | +394.9% | 109,700 | +338.8% | 0.29% | +197.9% |
| Q1 2019 | $1,734,000 | – | 25,000 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |